Pfenex Inc Revenue Growth Rates (PFNX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Pfenex Inc   (NYSEAMER: PFNX)
 

PFNX's Revenue Growth by Quarter and Year

Pfenex Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PFNX Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.78
1st Quarter March 0.68
FY 1.46

PFNXs Annual Revenue
Pfenex Inc 's Revenue in the fiscal year 2019 $ 50.33 millions
Pfenex Inc 's Revenue in the fiscal year 2018 $ 14.86 millions
Pfenex Inc 's Revenue in the fiscal year 2017 $ 28.78 millions
Pfenex Inc 's Revenue in the fiscal year 2016 $ 60.19 millions
Pfenex Inc 's Revenue in the fiscal year 2015 $ 9.58 millions




PFNX Revenue second quarter 2020 Y/Y Growth Comment
Pfenex Inc reported drop in Revenue in the second quarter 2020 by -72.21% to $ 0.78 millions, from the same quarter in 2019.
The fall in the second quarter 2020 Pfenex Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 196.05%.

Looking into second quarter 2020 results within Major Pharmaceutical Preparations industry 206 other companies have achieved higher Revenue growth. While Pfenex Inc ' s Revenue meltdown of -72.21% ranks overall at the positon no. 3701 in the second quarter 2020.


PFNX Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 554.03 % -81.3 % 227.42 %
3rd Quarter September - 327.17 % -28.88 % -89.72 %
2nd Quarter June -72.21 % -32.94 % 38.28 % -3.5 %
1st Quarter March -93.44 % 176.27 % 32.98 % 2.17 %
FY   - 238.69 % -48.37 % -

Financial Statements
Pfenex Inc 's second quarter 2020 Revenue $ 0.78 millions PFNX's Income Statement
Pfenex Inc 's second quarter 2019 Revenue $ 2.81 millions Quarterly PFNX's Income Statement


PFNX Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - 43.67 % -6.16 % 256.77 %
3rd Quarter September - 442.7 % -14.8 % 65.68 %
2nd Quarter June 14.85 % -72.88 % 11.73 % 7.45 %
1st Quarter March -96.9 % 209.25 % -79.06 % -48.45 %
FY (Year on Year)   - 238.69 % -48.37 % -


Back to PFNX Growth rate Comparisons >> Back to PFNX Growth rate Comparisons >>


Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #207
Healthcare Sector #539
Overall #3701

Revenue Y/Y Growth Statistics
High Average Low
2273.55 % 196.05 % -93.42 %
(Sep 30 2016)   (Mar 31 2020)
Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #207
Healthcare Sector #539
Overall #3701
Revenue Y/Y Growth Statistics
High Average Low
2273.55 % 196.05 % -93.42 %
(Sep 30 2016)   (Mar 31 2020)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Pfenex Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1457.38 % 105.52 % -96.89 %
(Sep 30 2016)  


PFNX's II. Quarter Q/Q Revenue Comment
Pfenex Inc achieved in the II. Quarter 2020 below company average Revenue rise of 14.85% quarter on quarter, to $ 0.78 millions.

II. Quarter 2020 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -72.88% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Pfenex Inc 's Revenue growth quarter on quarter, overall rank is 813.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #158
Overall #813
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #158
Overall #813
Revenue Q/Q Growth Statistics
High Average Low
1457.38 % 105.52 % -96.89 %
(Sep 30 2016)  


PFNX's II. Quarter Q/Q Revenue Comment
Pfenex Inc achieved in the II. Quarter 2020 below company average Revenue rise of 14.85% quarter on quarter, to $ 0.78 millions.

II. Quarter 2020 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -72.88% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Pfenex Inc 's Revenue growth quarter on quarter, overall rank is 813.


Pfenex Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)
Cumulative Revenue 12 Months Ending $ 38.62 $ 40.65 $ 50.33 $ 31.77 $ 20.09
Y / Y Revenue Growth (TTM) 92.18 % 89.29 % 238.74 % 8.01 % -34.91 %
Year on Year Revenue Growth Overall Ranking # 211 # 64 # 87 # 0 # 0
Seqeuential Revenue Change (TTM) -4.99 % -19.23 % 58.4 % 58.12 % -6.42 %
Seq. Revenue Growth (TTM) Overall Ranking # 2308 # 1513 # 100 # 20 # 378


Cumulative Revenue growth Comment
Although Pfenex Inc 's Annual Revenue growth year on year were below company's average 784.32% , Revenue announced in the Jun 30 2020 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 92.18% year on year, from 89.29% in Mar 31 2020.

In the Healthcare sector 62 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 64 to 211.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 63
Overall # 211

Revenue TTM Y/Y Growth Statistics
High Average Low
4306.08 %
 784.32 %
89.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 329
S&P 500 # 2308
Cumulative Revenue growth Comment
Although Pfenex Inc 's Annual Revenue growth year on year were below company's average 784.32% , Revenue announced in the Jun 30 2020 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 92.18% year on year, from 89.29% in Mar 31 2020.

In the Healthcare sector 62 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 64 to 211.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 63
Overall # 211

Revenue TTM Y/Y Growth Statistics
High Average Low
4306.08 %
784.32 %
89.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 329
S&P 500 # 2308




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PFNX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2020
Integrated Biopharma Inc-0.36%$ -0.361 millions
Conformis inc -0.64%$ -0.638 millions
Nrc Health-0.79%$ -0.789 millions
Chimerix Inc -0.99%$ -0.989 millions
Prestige Consumer Healthcare Inc -1.19%$ -1.189 millions
Amedisys Inc-1.61%$ -1.608 millions
Sanara Medtech Inc -1.67%$ -1.667 millions
Endo International Plc-1.73%$ -1.735 millions
Sunlink Health Systems Inc -1.93%$ -1.927 millions
Novo Nordisk A-1.96%$ -1.960 millions
Healthcare Services Group Inc -2.18%$ -2.180 millions
Eli Lilly And Company-2.44%$ -2.436 millions
Myomo Inc -2.47%$ -2.472 millions
Icu Medical Inc-2.85%$ -2.851 millions
Reliv International Inc-2.91%$ -2.912 millions
Quanterix Corporation-3.00%$ -2.999 millions
United Therapeutics Corporation-3.10%$ -3.105 millions
Immunogen inc -3.33%$ -3.326 millions
Hologic Inc-3.46%$ -3.461 millions
Avantor Inc -3.50%$ -3.504 millions
Nature s Sunshine Products inc -3.79%$ -3.790 millions
American Renal Associates Holdings Inc -3.80%$ -3.800 millions
Healthlynked Corp-3.88%$ -3.880 millions
Labcorp Holdings Inc -3.92%$ -3.918 millions
Steris Plc-4.00%$ -4.000 millions
Mylan N v -4.22%$ -4.219 millions
Medpace Holdings Inc -4.25%$ -4.254 millions
Baxter International Inc -4.30%$ -4.296 millions
Pra Health Sciences Inc -4.38%$ -4.378 millions
Universal Health Services Inc -4.39%$ -4.393 millions


About Pfenex Inc Revenue Growth Rates (PFNX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.